engleski

Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat

After demonstration that cysteamine induced duodenal lesions in gastrectomized rats, while a number of antiulcer drugs mitigated these lesions, it was shown that one single intrarectal (i.r.) cysteamine application produced severe colon lesions in acute studies in rats. Thus, the further focus was on the protracted effect of cysteamine colon challenge (400 mg/kg b.w. i.r.) and therapy influence in chronic experiments in female rats. Regularly, cysteamine colon lesion were markedly mitigated by ranitidin (10), omeprazole (10), atropine (10), methylprednisolone (1), sulphasalazine (50 ; mg/kg), pentadecapeptide BPC 157 (PL-10, PLD-116 ; 10 microgram or 10 nanogram/kg). Specifically, after 1 or 3 months following initial challenge ( cysteamine 400 mg/kg i.r.) in female rat, the therapy ((BPC 157 (PL-10, PLD-116 (10.0 microgram or 10.0 nanogram/kg ; i.g., i.p., i.r.), ranitidine, omeprazole, atropine, methylpradnisolone, sulphasalazine (i.p.)) reversed the protracted cysteamine colon injury: the 1 week-regimen (once daily application) started after 1 month post-cysteamine, as well as the 2 weeks-regimen (once daily application), which started after 3 months. The effect on recidive lesio was also tasted. These cysteamine lesions may reappear after stopping therapy ( after stopping therapy for 3 weeks at the end of 2 weeks-regimen started i 3 month-cysteamine female rats) in sulphasalazine group, while this reappearance in markedly antagonized i pentadecapeptide BPC 157 (PL-10, PLD-116)-rats (cysteamine-colon lesion still substantially low).

Cysteamine chronic colon lesions; Recidive; Pentadecapeptide BPC 157; Gastroduodenal antiulcer agents; Remedies for inflammatory bowel disease

nije evidentirano